Investigational New Drugs (IND)

Investigational New Drugs is an international peer reviewed medical journal focused on the discovery, development, and clinical evaluation of novel therapeutic agents, particularly in oncology and experimental medicine. The journal publishes original research articles, clinical trial reports, reviews, and translational studies related to new drugs, targeted therapies, biologics, immunotherapies, and anticancer treatments. The journal emphasizes all stages of drug development, including preclinical pharmacology, toxicology, pharmacokinetics, pharmacodynamics, biomarker studies, and phase I to phase III clinical trials. It also covers precision medicine, molecular targeted therapies, combination treatments, cancer genomics, and innovative therapeutic strategies designed to improve patient outcomes. Investigational New Drugs is widely recognized by oncologists, pharmacologists, clinical researchers, and pharmaceutical scientists for its contribution to translational and clinical drug research. The journal is indexed in major scientific databases including PubMed, MEDLINE, Scopus, EMBASE, and Web of Science.

Investigational New Drugs (IND) is :-

• International, Peer-Reviewed, Open Access, Refereed, Oncology, Pharmacology, Drug Discovery and Development, Experimental Therapeutics, Clinical Trials, Molecular Medicine, Cancer Research, Precision Medicine, Translational Medicine, translational studies related to new drugs, targeted therapies, biologics, immunotherapies, anticancer treatments, preclinical pharmacology, toxicology, pharmacokinetics, pharmacodynamics, biomarker studies, phase I to phase III clinical trials, precision medicine, molecular targeted therapies, combination treatments, cancer genomics, innovative therapeutic strategies designed to improve patient outcomes , Online or Print , Bi-Monthly Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 0167-6997, E-ISSN: 1573-0646, Established: 1983,
• Provides Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE